WALTHAM, Mass., Aug. 16 /PRNewswire-FirstCall/ — Interleukin
Genetics, Inc. (OTCQB: ILIU) today announced that trading of
shares of the Company’s common stock will be transferred from the
NYSE Amex to the OTCQB™ Marketplace effective today, August
16, 2010. Investors in the Company can trade the stock easily in
this marketplace, where Interleukin Genetics’ symbol will now be
ILIU. The OTCQB market tier was recently introduced to better
distinguish OTC securities that are registered and fully reporting
with the Securities and Exchange Commission (SEC) or a banking or
insurance regulator. Investors can now view real time stock quotes
for ILIU at http://www.otcmarkets.com.
“Trading on the OTCQB brings a level of market maker
transparency, which is good for our shareholders. Our
marketplace transfer will enable the Company to stay focused on
dedicating resources to partnering and driving continued revenue
growth of our Inherent Health brand of genetic tests,” said Lewis
H. Bender, CEO. “We just announced a significant increase in
quarterly revenue and a new major funded partnership. We will
continue to pursue additional relationships with companies involved
in markets that align with our products.”
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets
genetic tests that empower consumers to prevent chronic diseases
and that assist pharmaceutical companies in the development and
marketing of targeted therapeutics. The Company leverages its
research, intellectual property and biomarker development
experience to facilitate the emerging personalized health market.
Interleukin Genetics markets a line of genetic tests under the
Inherent Health brand including Bone Health, Weight Management,
Heart Health and Nutritional Needs. The Company is headquartered in
Waltham, MA. For more information please visit
SOURCE
